

January 19, 2024

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001**

Ref: Scrip Code: 543322

**To,
The Manager - Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Name: GLS

Dear Sir/Madam,

Sub: Glenmark Life Sciences Signs Master Supply Agreement with a leading Japanese innovator pharmaceutical company

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you

Yours faithfully,
For Glenmark Life Sciences Limited

**Rudalf Corriea
Company Secretary & Compliance Officer
Encl: As above**

Glenmark Life Sciences announces another CDMO deal

Signs Master Supply Agreement with a leading Japanese innovator pharmaceutical company

To manufacture and supply API in the therapeutic area of Urinary Anti-Spasmodic

Mumbai, January 19, 2024: Glenmark Life Sciences Limited (GLS), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced the signing of a Master Supply Agreement (MSA) with a Japanese innovator pharmaceutical company with global presence in Europe, United States and Asia. Under the aegis of the Master Supply Agreement, Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator.

Glenmark Life Sciences will leverage its expertise in API manufacturing to support the global pharmaceutical innovator's initiative in the field of urinary anti-spasmodic therapeutics. As part of this collaboration, product portfolios of various affiliates of the global innovator may also be added in the future. The API for the finished formulation will be supplied to all major regulated markets such as United States, Europe and Japan. The estimated commercial value of this project is expected to be around \$5million.

According to **Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences**, "This collaboration is part of our continued efforts in the CDMO space to contribute to the advancements in healthcare while expanding our global footprint. As a reliable partner we will combine our API knowledge in cGMP manufacturing and extend our expertise in regulatory filing with global agencies across multiple geographies. We are committed to fostering strategic alliances that drive innovation and this is a long term commitment. Going forward I am sure this will not only consolidate our strategic partnership but also open doors for other collaborations."

About Glenmark Life Sciences Ltd (GLS)

Glenmark Life Sciences Limited (BSE: 543322, NSE: GLS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and speciality pharmaceutical companies.

It has a diversified portfolio of 142 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world (ROW). The company's 4 manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1198 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). GLS is a subsidiary of Glenmark Pharmaceuticals Limited and is listed on BSE/NSE.

Learn more about Glenmark Life Sciences Limited on [www. https://www.glenmarklifesciences.com/](https://www.glenmarklifesciences.com/)

For any further queries please contact:

Soumi Rao | General Manager – Corporate Communications

Email: Soumi.Rao@glenmarklifesciences.com

Mobile: 9870196931